These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 21856691

  • 1. Population-based incidence of exudative age-related macular degeneration and ranibizumab treatment load.
    Geirsdottir A, Jonsson O, Thorisdottir S, Helgadottir G, Jonasson F, Stefansson E, Sigurdsson H.
    Br J Ophthalmol; 2012 Mar; 96(3):444-7. PubMed ID: 21856691
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration.
    Cunningham ET, Feiner L, Chung C, Tuomi L, Ehrlich JS.
    Ophthalmology; 2011 Dec; 118(12):2447-52. PubMed ID: 21872935
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [Abstract] [Full Text] [Related]

  • 12. Age-related macular degeneration, anti-vascular endothelial growth factor agents, and short-term mortality: a postmarketing medication safety and surveillance study.
    French DD, Margo CE.
    Retina; 2011 Jun; 31(6):1036-42. PubMed ID: 21836410
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
    Papadopoulou DN, Mendrinos E, Mangioris G, Donati G, Pournaras CJ.
    Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Intravitreal ranibizumab in the treatment of predominantly hemorrhagic lesions in exudative age-related macular degeneration.
    Konstantinidis L, Mantel I, Zografos L, Ambresin A.
    Klin Monbl Augenheilkd; 2011 Apr; 228(4):288-92. PubMed ID: 21484631
    [Abstract] [Full Text] [Related]

  • 19. One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections.
    Arias L, Roman I, Masuet-Aumatell C, Rubio MJ, Caminal JM, Catala J, Pujol O.
    Retina; 2011 Apr; 31(7):1261-7. PubMed ID: 21499194
    [Abstract] [Full Text] [Related]

  • 20. Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting.
    Querques G, Azrya S, Martinelli D, Berboucha E, Feldman A, Pece A, Coscas G, Soubrane G, Souied EH.
    Br J Ophthalmol; 2010 Mar; 94(3):292-6. PubMed ID: 19951942
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.